Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Repetitive antidotal treatment is crucial in eliminating eye pathology, respiratory toxicity and death following whole-body VX vapor exposure in freely moving rats.

Bloch-Shilderman E, Yacov G, Cohen L, Egoz I, Gutman H, Gez R, Rabinovitz I, Nili U.

Arch Toxicol. 2019 Feb 7. doi: 10.1007/s00204-019-02401-0. [Epub ahead of print]

PMID:
30729277
2.

Determining a threshold sub-acute dose leading to minimal physiological alterations following prolonged exposure to the nerve agent VX in rats.

Bloch-Shilderman E, Rabinovitz I, Egoz I, Yacov G, Allon N, Nili U.

Arch Toxicol. 2018 Feb;92(2):873-892. doi: 10.1007/s00204-017-2108-5. Epub 2017 Nov 10.

PMID:
29127449
3.

Propagation of damage in the rat brain following sarin exposure: Differential progression of early processes.

Lazar S, Egoz I, Brandeis R, Chapman S, Bloch-Shilderman E, Grauer E.

Toxicol Appl Pharmacol. 2016 Nov 1;310:87-97. doi: 10.1016/j.taap.2016.09.008. Epub 2016 Sep 14.

PMID:
27639427
4.

Synergism Between Anticholinergic and Oxime Treatments Against Sarin-Induced Ocular Insult in Rats.

Gore A, Brandeis R, Egoz I, Turetz J, Nili U, Grauer E, Bloch-Shilderman E.

Toxicol Sci. 2015 Aug;146(2):301-10. doi: 10.1093/toxsci/kfv092. Epub 2015 May 7.

PMID:
25956921
5.

Efficacy assessment of a combined anticholinergic and oxime treatment against topical sarin-induced miosis and visual impairment in rats.

Gore A, Bloch-Shilderman E, Egoz I, Turetz J, Brandeis R.

Br J Pharmacol. 2014 May;171(9):2364-74. doi: 10.1111/bph.12586.

6.

Magnesium sulfate treatment against sarin poisoning: dissociation between overt convulsions and recorded cortical seizure activity.

Katalan S, Lazar S, Brandeis R, Rabinovitz I, Egoz I, Grauer E, Bloch-Shilderman E, Raveh L.

Arch Toxicol. 2013 Feb;87(2):347-60. doi: 10.1007/s00204-012-0916-1. Epub 2012 Sep 28.

PMID:
23052190
7.

Early in vivo MR spectroscopy findings in organophosphate-induced brain damage-potential biomarkers for short-term survival.

Shrot S, Anaby D, Krivoy A, Makarovsky I, Rosman Y, Bloch-Shilderman E, Lazar S, Bar-Shir A, Cohen Y.

Magn Reson Med. 2012 Nov;68(5):1390-8. doi: 10.1002/mrm.24155. Epub 2012 Jan 13.

8.

Efficacy assessment of various anticholinergic agents against topical sarin-induced miosis and visual impairment in rats.

Gore A, Brandeis R, Egoz I, Peri D, Turetz J, Bloch-Shilderman E.

Toxicol Sci. 2012 Apr;126(2):515-24. doi: 10.1093/toxsci/kfs009. Epub 2012 Jan 12.

PMID:
22247005
9.

Deterioration in brain and heart functions following a single sub-lethal (0.8 LCt50) inhalation exposure of rats to sarin vapor: a putative mechanism of the long term toxicity.

Allon N, Chapman S, Egoz I, Rabinovitz I, Kapon J, Weissman BA, Yacov G, Bloch-Shilderman E, Grauer E.

Toxicol Appl Pharmacol. 2011 May 15;253(1):31-7. doi: 10.1016/j.taap.2011.03.007. Epub 2011 Mar 15.

PMID:
21419149
10.

Subchronic exposure to low-doses of the nerve agent VX: physiological, behavioral, histopathological and neurochemical studies.

Bloch-Shilderman E, Rabinovitz I, Egoz I, Raveh L, Allon N, Grauer E, Gilat E, Weissman BA.

Toxicol Appl Pharmacol. 2008 Aug 15;231(1):17-23. doi: 10.1016/j.taap.2008.03.024. Epub 2008 Apr 11.

PMID:
18485435
11.

Transient and reversible nephrotoxicity of sarin in rats.

Bloch-Shilderman E, Levy A.

J Appl Toxicol. 2007 Mar-Apr;27(2):189-94.

PMID:
17154277
12.

Subcellular alterations of protein kinase C isozymes in the rat brain after organophosphate poisoning.

Bloch-Shilderman E, Kadar T, Levy A, Sahar R, Rabinovitz I, Gilat E.

J Pharmacol Exp Ther. 2005 Jun;313(3):1082-9. Epub 2005 Feb 16.

PMID:
15716382
13.

Pardaxin stimulation of phospholipases A2 and their involvement in exocytosis in PC-12 cells.

Bloch-Shilderman E, Abu-Raya S, Trembovler V, Boschwitz H, Gruzman A, Linial M, Lazarovici P.

J Pharmacol Exp Ther. 2002 Jun;301(3):953-62.

PMID:
12023524
14.
15.

Involvement of extracellular signal-regulated kinase (ERK) in pardaxin-induced dopamine release from PC12 cells.

Bloch-Shilderman E, Jiang H, Abu-Raya S, Linial M, Lazarovici P.

J Pharmacol Exp Ther. 2001 Mar;296(3):704-11.

PMID:
11181896
16.

Characterization of pardaxin-induced dopamine release from pheochromocytoma cells: role of calcium and eicosanoids.

Abu-Raya S, Bloch-Shilderman E, Lelkes PI, Trembovler V, Shohami E, Gutman Y, Lazarovici P.

J Pharmacol Exp Ther. 1999 Feb;288(2):399-406.

PMID:
9918538
17.

Pardaxin, a new pharmacological tool to stimulate the arachidonic acid cascade in PC12 cells.

Abu-Raya S, Bloch-Shilderman E, Shohami E, Trembovler V, Shai Y, Weidenfeld J, Yedgar S, Gutman Y, Lazarovici P.

J Pharmacol Exp Ther. 1998 Dec;287(3):889-96.

PMID:
9864269
18.

Isolation, characterization and synthesis of a novel paradaxin isoform.

Adermann K, Raida M, Paul Y, Abu-Raya S, Bloch-Shilderman E, Lazarovici P, Hochman J, Wellhöner H.

FEBS Lett. 1998 Sep 18;435(2-3):173-7.

Supplemental Content

Loading ...
Support Center